Determination of metabolic syndrome and insulin resistance rate among adults with ultrasound diagnosed non-alcoholic fatty liver disease

Metabolic syndrome (MS) has close association with nonalcoholic fatty liver disease (NAFLD) and is characterized by insulin insensitivity, central obesity, dyslipidemia, hypertension and high glucose levels. This study aimed to define the prevalence of MS, insulin resistance and diabetes among subjects with NAFLD. Patients and method: In a tertiary center, patients diagnosed to have fatty liver disease by ultrasound were included. Cases with drug and/or alcohol use and liver diseases were excluded. Anthropometric measures were applied. Fasting glucose, insulin, c-peptide and transaminase levels were measured. Oral glucose tolerance test was applied to all cases. Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) index was calculated. Insulin resistance was defined as HOMA-IR ≥2.7. ATP III criteria were applied for diagnosis of MS. 230 patients were enrolled. 141 patients (61.3%) were female. Mean age was 50.3±10 (18-95) years. Mean body-mass index (BMI) was 30.5±10.6 (18- 50). Mean HOMA index was 3.3±2.6 (0.5-26.5). Impaired fasting glycemia was diagnosed in 78 (33.9%) patients, while impaired glucose tolerance and type 2 diabetes were diagnosed in 65 (28.3%) and 51 (22.1%) patients, respectively. MS prevalence among patients with NAFLD was 56.5%. MS was present in 73.2% of patients with HOMA index ≥ 2.7. Independently from BMI, insulin resistance is high in patients with NAFLD. Transaminase levels did not change with MS among NAFLD patients. NAFLD is associated with increased prevalence rate for metabolic syndrome, insulin resistance and type 2 diabetes.

PDF

___

1. Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: An Agenda for clinical research. Hepatology. 2002; 35:746-52.

2. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology, 2018;1:328-57.

3. Naga Chalasani N, Younossi ZM, Lavine JE, et al. The diagnosis and management of non alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005-23.

4. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–55.

5. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-85.

6. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;16:1221- 31.

7. Williams CD, Stengel J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middleaged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–31.

8. Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of non- alcoholic fatty liver disease in the United States: The Third National Health and Nutrition Examination Survey, 1998-1994. Am J Epidemiyol. 2013;178:38-45.

9. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.

10. Farrell GC. Nonalcoholic steatohepatitis: What is it, and why is it important in the Asia- Pasific region? J Gastroenterol Hepatol. 2003;18:124-38.

11. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Final Report [no authors listed]. Circulation 2003;106:3143–420.

12. Kim D, Touros A, Kim WR. Nonalcoholic fatty liver disease and metabolic syndrome. Clin Liver Dis. 2018;22:133-40.

13. Fulop T, Tessier D, Carpentier A. The metabolic syndrome. Pathologie Biologie. 2006;54:375-86.

14. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American heart association /national heart, lung and blood insitute scientific statement. Circulation. 2005;112:2735-52.

15. Grundy SM, Cleeman JI, Daniels SR. et al. Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement: executive summary. Crit Pathw Cardiol, 2005;4:198-203.

16. Wainwright P, Byrne CD. Bidirectional relationships and disconnects between NAFLD and features of the metabolic syndrome. Int J Mol Sci. 2016;17:367.

17. Marchesini G, Forlani G, Bugianesi E, et al. Nonalcoholic fatty liver, steatohepatitis and metabolic syndrome. Hepatology. 2003;37:917-23.

18. AMERICAN DIABETES ASSOCIATION. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011; 34 (supplement): 11-61.

19. Chobanian AV, Bakris GL, Black HR,et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA. 2003;289:2560-72.

20. Siqueira ACG, Cotrim HP, Rocha R, et al. Nonalcoholic fatty liver disease and insulin resistance: importance of risk factors and histological spectrum. Eur J Gastroenterol Hepatol. 2005;17:837-841.

21. Bonora E, Kiehl S, Willeit J, et al. Prevalance of insulin resistance in metabolic disorders. Diabetes. 1998;47:1643-9.Med Science 2021;10(1):25- 30.

22. Matteoni CA,Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-9.

23. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373-9.

24. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450-5.

25. Hanson RL, Imperatore G, Bennett PH, et al. Components of the "Metabolic Syndrome" and incidence of type 2 diabetes. Diabetes. 2002;51:3120-7.

26. Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care. 2002;25:1790-4.

27. Ford ES, Giles WH, Dietz WH. Prevalence of metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-59.

28. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as predictor of nonalcoholic fatty liver disease. Ann of Int Med. 2005;143:722- 8.

29. Joseph AE, Saverymuttu SH, al-Sam S, et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol. 1991;43:26-31.

30. Ampuero J, Aller R, Gallego-Durán R, et al. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther. 2018;48:1260-70.

31. Saely CH, Aczel S, Marte T, The metabolic syndrome, insulin resistance and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metabolism. 2005;90:5698-703.

32. Satman I, Yılmaz T, Sengül A, et al. Population-based study of diabetes and risk characteristics in Turkey; the results of Turkish Diabetes Epidemiology Study (TURDEP). Diabetes Care. 2002:4:1551-6.

33. Sargin M, Bayramiçli UO, Sargin H, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Is OGGT indicated in nonalcoholic fatty liver disease? J Clin Gastroenterol. 2003;37:399-402.

34. Oh SY, Cho YK, Kang MS, et al. The association between increased alanine aminotransferase activity and metabolic factors in in nonalcoholic fatty liver disease. Metabolism Clin Experimental. 2006;5:1604-9.

35. Fan JG, Zhu J, Li XJ, et al. Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol. 2005;20:1825-32.

36. Seppala Lindroos A, Vehkavaara S, Hakinken AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metabolism. 2002;87:3023-8.

37. Sniderman AD, Furberg CD, Keech A. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin therapy. Lancet, 2003;361:777-80.

38. Sattar N, Williams K, Sniderman AD, et al. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with factors in patients with the metabolic syndrome in the insulin resistance atherosclerosis study. Circulation. 2004;110:2687-93.